The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
Authors:
- Carly de Faria CoelhoCCCarly de Faria Coelho
- Rodolfo P. VieiraRodolfo P. Vieira
- Osvaldo Soares Araújo-JuniorOAOsvaldo Soares Araújo-Junior
- Pedro Sardinha Leonardo Lopes-MartinsPLPedro Sardinha Leonardo Lopes-Martins
- Larissa Gomes dos SantosLSLarissa Gomes dos Santos
- Lucas Danilo DiasLucas Danilo Dias
- Alberto Souza de Sá FilhoAlberto Souza de Sá Filho
- Patrícia Sardinha LeonardoPLPatrícia Sardinha Leonardo
- Sandro Dutra e SilvaSSSandro Dutra e Silva
- Rodrigo Alvaro Brandão Lopes-MartinsRLRodrigo Alvaro Brandão Lopes-Martins
Open Access
Abstract
Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms “cannabidiol” and “anxiety”. Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD’s potential efficacy across different conditions.Keywords
Funding Information
- Goiás Research Foundation (FAPEG) (04/2024, 07586/2023-5)
- National Council for Scientific and Techno-logical Development (CNPq) (04/2024, 07586/2023-5)
This publication has 40 references indexed in Scilit:
- The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trialPsychopharmacology, 2023
- Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabisPsychopharmacology, 2022
- The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyPsychopharmacology, 2022
- Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorderPsychopharmacology, 2022
- Constituents of Cannabis Sativa2020
- Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosisPsychopharmacology, 2020
- Synthetic Strategies for (−)‐Cannabidiol and Its Structural AnalogsChemistry – An Asian Journal, 2019
- Cannabidiol: An Overview of Some Pharmacological AspectsThe Journal of Clinical Pharmacology, 2002
- Individual-patient monitoring in clinical practice: are available health status surveys adequate?Quality of Life Research, 1995
- Antianxiety effect of cannabidiol in the elevated plus-mazePsychopharmacology, 1990